Eric Green

366 posts

Eric Green

@ercgrn

Physician-scientist-entrepreneur. Biotech CEO/CSO. Genetics, biotech, birds (mostly raptors), books.

San Mateo, CA Katılım Ocak 2011

561 Takip Edilen529 Takipçiler

Eric Green retweetledi

Jeremy Leipzig@jermdemo·29 Oca

OK, so the $ bio ai assistants are: Ascent Bio - ascentbio.ai Bio Protocol BIOS - ai.bio.xyz Edison Scientific - edisonscientific.com K-Dense - k-dense.ai Potato - potato.ai SciSpace - scispace.com/biomedical/ Did I miss any?

Italiano

342

31.8K

Eric Green retweetledi

FrattaLab@FrattaLab·25 Haz

We find TDP-43 loss to cause presynaptic defects, which are rescued by ASOs correcting a single cryptic exon in UNC13A. Surprising effect of just one cryptic exon and promising strategy for ALS! Matt Keuss @PeteHarley95 in great collaboration with @jbneuro biorxiv.org/content/10.110…

English

13K

Eric Green@ercgrn·24 Haz

Beautiful work from Pietro Fratta, Juan Burrone groups linking TDP-43 to synaptic function with UNC13A as key mediator. Combined with human genetics, strengthens case for UNC13A as promising target for patients with ALS.

bioRxiv@biorxivpreprint

Loss of TDP-43 induces synaptic dysfunction that is rescued by UNC13A splice-switching ASOs biorxiv.org/cgi/content/sh… #bioRxiv

English

1.6K

Eric Green@ercgrn·22 May

Nice example of integrating human genetics, functional genomics and protein structure to understand disease biology. Congrats @artwuster @karls_es and team.

Art Wuster@artwuster

There are haploinsufficiencies that are caused almost entirely by missense variants instead of truncating mutations. Those genes are more vulnerable to missense variants disrupting their function, and SLC6A1 is an example. Here's our paper: cell.com/ajhg/fulltext/…

English

723

Eric Green@ercgrn·3 Mar

Fascinating NYTimes article on quest to understand causes of Kawasaki nytimes.com/2024/02/27/hea…

English

140

Eric Green retweetledi

Michael Baym@baym·19 Oca

If there was only one scientific practice I could teach to every scientist regardless of stage or field I think it would be: look at the data. Spot check it. Find a few data points and trace them through to see if they make sense. Look at the raw data. Don't just do analyses.

English

216

1.2K

215.2K

Eric Green@ercgrn·18 Oca

@RCSunlab @MazeInBiotech Great working with you over the past few years and watching metabolomics technology mature in front of our eyes.

English

Ramon Sun@RCSunlab·18 Oca

it was humbling to be part of this huge collaborative and translational effort led by @MazeInBiotech @ercgrn great example of how #metabolomics and #Spatialmetabolomics can be part of the clinical pipeline!

Maze Therapeutics@MazeInBiotech

We're thrilled to share our manuscript "Small-molecule inhibition of GYS1 for the treatment of Pompe disease and other glycogen storage disorders,” featured as the cover story of the latest @ScienceMagazine. Congrats to our team on this exciting research! #editor-abstract" target="_blank" rel="nofollow noopener">science.org/doi/10.1126/sc…

English

1.1K

Eric Green@ercgrn·18 Oca

@TravisHinson @ScienceTM Thanks @TravisHinson - enjoyed your new study on CRISPRa for TTN as well!

English

Travis Hinson@TravisHinson·18 Oca

@ercgrn @ScienceTM Nice work Eric. I remember hearing about this exciting approach to treat glycogen storage diseases more broadly than previously available in the clinic. Amazing progress!

English

Eric Green@ercgrn·18 Oca

Now out in @ScienceTM A novel small molecule approach to treat patients with Pompe disease (who have impaired glycogen breakdown) by blocking the production of glycogen. science.org/doi/10.1126/sc… 1/x

English

4.3K

Eric Green@ercgrn·18 Oca

Complements exciting phase 1 clinical data showing gys1 inhibition reduces glycogen in muscle and peripheral blood in healthy volunteers and supports advancing to patients. mazetx.com/maze-therapeut… 3/3

English

124

Eric Green@ercgrn·18 Oca

We show that inhibiting glycogen synthase (SRT) reduces glycogen accumulation and corrects muscle metabolism in a mouse model of Pompe, as monotherapy or combined with enzyme replacement (ERT). 2/3

English

162

Eric Green retweetledi

Daniel J Drucker@DanielJDrucker·18 Oca

Here, substrate reduction therapy with GYS1 inhibition may be a promising therapeutic approach for Pompe disease and other glycogen storage diseases @ScienceTM science.org/doi/10.1126/sc…

English

2.9K

Eric Green retweetledi

JASN_News@JASN_News·12 Eki

A variant of APOL1, p.N264K, is associated with reduced risk of CKD and ESKD among carriers of APOL1 high risk variants to levels comparable to individuals with APOL1 low-risk genotypes bit.ly/JASN0219 @DrFlashHeart @MichaelEMatheny @KSusztak @Eddiesiew2 @CassyRCohen

English

3.2K

Eric Green@ercgrn·6 Eki

Initial data on our small molecule APOL1 pore inhibitor shared at @ASNKidney 2022 with exciting updates to come at Kidney Week 2023. We expect to enter the clinic this year.

English

879

Eric Green@ercgrn·6 Eki

Study ids and functionalizes a renal protective variant in APOL1, implicating ion conductance as pathologic mechanism for APOL1 kidney dz. This mechanism has been further validated by @VertexPharma POC study of APOL1 pore inhibitor in FSGS @NEJM.

English

132

Eric Green@ercgrn·6 Eki

New pub from our team @MazeInBiotech with VA MVP demonstrating key piece of our approach: human genetics -> mechanism -> medicine See great thread below from @DrFlashHeart

Caitlyn Vlasschaert@DrFlashHeart

Sharing exciting new work led by Adriana Hung, Alex Bick (@AlexBickMDPhD) and Eric Green (@ercgrn): Genetic inhibition of APOL1 Pore Forming Function Prevents APOL1-Mediated Kidney Disease A brief 🧵: journals.lww.com/jasn/fulltext/…

English

2.8K

Eric Green retweetledi

Sek Kathiresan MD@skathire·6 Eki

A mutation in APOL1 that protects against kidney disease. How does it work? Seems to reduce APOL1 pore function Cool new work integrating human genetics with cellular APOL1 function. 👏@alexbickmdphd @ercgrn @MazeInBiotech journals.lww.com/jasn/fulltext/…

English

15.2K

Eric Green@ercgrn·2 May

@skathire @MazeInBiotech @sanofi Thanks @skathire. Exciting to continue building on genetic foundations to develop medicines for rare and common disease.

English

101

Sek Kathiresan MD@skathire·1 May

@MazeInBiotech out-license MZE001 - glycogen synthase inhibitor - for the treatment of Pompe disease to @sanofi substrate reduction therapy $150M upfront & up to $600M in milestones Tremendous validation of team & approach Congrats to J. Coloma, H. Bernstein, @ercgrn & team

Maze Therapeutics@MazeInBiotech

We've signed an exclusive license agreement w/ @Sanofi for MZE001, an investigational compound in development for #Pompe disease, enabling a potentially important addition to the treatment paradigm. We're thankful to Sanofi & proud of our 1st program. businesswire.com/news/home/2023…

English

7.7K

Eric Green@ercgrn·2 May

@Dr_RajatGupta Thanks @Dr_RajatGupta ! A nice example of how we can integrate rare disease genetics (validated role of GYS1 in humans) with biobank analyses (to understand safety of modulation) to support drug discovery.

English

Raj Gupta@Dr_RajatGupta·1 May

Congrats @ercgrn ! Exciting news for anyone that uses genetics to inform drug discovery (so…everyone).

Maze Therapeutics@MazeInBiotech

English

1.7K

Eric Green retweetledi

Sasha Gusev@SashaGusevPosts·16 Nis

A 🧵 on some of my intuitions/priors about the genetics of complex and molecular traits in humans (i.e. what I think of as typical), largely motivated by GWAS/QTL studies over the past decade [citing papers with nice figures where possible]

English

245

717

268.8K

Keşfet

@PeteHarley95 @jbneuro @artwuster @karls_es @RCSunlab @MazeInBiotech @TravisHinson @ScienceTM